{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:32:45Z","timestamp":1786487565045,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004386","name":"University of Malaya","doi-asserted-by":"crossref","award":["Grant code: RP008D-13HTM"],"award-info":[{"award-number":["Grant code: RP008D-13HTM"]}],"id":[{"id":"10.13039\/501100004386","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004386","name":"University of Malaya","doi-asserted-by":"crossref","award":["Grant code: RP008D-13HTM"],"award-info":[{"award-number":["Grant code: RP008D-13HTM"]}],"id":[{"id":"10.13039\/501100004386","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Malaysian Ministry of Higher Education under the Fundamental Research Grant Scheme","award":["FRGS\/1\/2019\/SKK03\/UM\/01\/1"],"award-info":[{"award-number":["FRGS\/1\/2019\/SKK03\/UM\/01\/1"]}]},{"name":"Malaysian Ministry of Higher Education under the Fundamental Research Grant Scheme","award":["FRGS\/1\/2019\/SKK03\/UM\/01\/1"],"award-info":[{"award-number":["FRGS\/1\/2019\/SKK03\/UM\/01\/1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Locally advanced breast cancer (LABC) frequently requires neoadjuvant chemotherapy (NAC), and early, non-contrast imaging biomarkers are of increasing clinical interest for monitoring treatment response. Diffusion-weighted imaging (DWI) and intravoxel incoherent motion (IVIM) MRI provide quantitative measures of tumour microstructure without gadolinium administration. To evaluate whether the apparent diffusion coefficient (ADC) and true diffusion (Dt) derived from IVIM can serve as early non-contrast imaging biomarkers of NAC response in patients with LABC. Fourteen women with biopsy-proven LABC underwent MRI at baseline (T0), after the first NAC cycle (T1), and after the third cycle (T2). ADC was calculated from b\u2009=\u20090 and 1000\u00a0s\/mm\u00b2, while Dt, Dp, and f were obtained using a full bi-exponential IVIM model incorporating all b-values (0\u20131000\u00a0s\/mm\u00b2). Only four patients completed all three MRI timepoints. Tumour diameter and diffusion parameters were compared across time. At baseline, ADC and Dt were significantly lower in malignant lesions compared with contralateral fibroglandular tissue (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). Following NAC, mean tumour ADC increased by 27.2% at T1 and 39.5% at T2, accompanied by progressive tumour size reduction (50.9% at T2). Dt demonstrated a similar upward trend. Perfusion-related IVIM parameters (Dp and f) showed no consistent differences. ROC analysis demonstrated high discriminatory performance of ADC for differentiating invasive ductal carcinoma from normal tissue (AUC\u2009=\u20091.00), although this finding must be interpreted cautiously given the small sample size. ADC and Dt showed early increases following NAC that paralleled reductions in tumour size, supporting their potential as practical, contrast-free imaging biomarkers of treatment-related microstructural changes. However, the limited number of complete longitudinal datasets (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20094) and the pilot nature of the study require cautious interpretation. Larger prospective studies are needed to validate these findings.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-51568-x","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:24:08Z","timestamp":1779355448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Apparent diffusion coefficient and intravoxel incoherent motion-derived true diffusion serve as early non-contrast longitudinal biomarkers of neoadjuvant chemotherapy response"],"prefix":"10.1038","volume":"16","author":[{"given":"M. F. A.","family":"Kamis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-9076","authenticated-orcid":false,"given":"K.","family":"Rahmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-0621","authenticated-orcid":false,"given":"M. T.","family":"Ramli Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fadzli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. I.","family":"Rozalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. W.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. A.","family":"Mohd Taib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. D.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"51568_CR1","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.breast.2021.12.011","volume":"62","author":"S Aebi","year":"2022","unstructured":"Aebi, S., Karlsson, P. & Wapnir, I. L. Locally advanced breast cancer. Breast 62, S58\u2013S62 (2022).","journal-title":"Breast"},{"key":"51568_CR2","first-page":"3","volume":"8","author":"MVB Cruz-Ordinario","year":"2023","unstructured":"Cruz-Ordinario, M. V. B. et al. Neoadjuvant systemic therapy for locally advanced breast cancer: A 10-year experience. Asian Pac. J. Cancer Care. 8, 3\u20139 (2023).","journal-title":"Asian Pac. J. Cancer Care"},{"key":"51568_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s43055-020-00175-5","volume":"51","author":"S Iranmakani","year":"2020","unstructured":"Iranmakani, S. et al. Review of various modalities in breast imaging: technical aspects and clinical outcomes. Egypt. J. Radiol. Nucl. Med. 51, 120 (2020).","journal-title":"Egypt. J. Radiol. Nucl. Med."},{"key":"51568_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.amjmed.2012.11.025","volume":"126","author":"JS Drukteinis","year":"2013","unstructured":"Drukteinis, J. S., Mooney, B. P., Flowers, C. I. & Gatenby, R. A. Beyond mammography: New frontiers in breast cancer screening. Am. J. Med. 126, 472\u2013479 (2013).","journal-title":"Am. J. Med."},{"key":"51568_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fradi.2021.735567","volume":"1","author":"DE Frankhouser","year":"2021","unstructured":"Frankhouser, D. E., Dietze, E., Mahabal, A. & Seewaldt, V. L. Vascularity and dynamic contrast-enhanced breast magnetic resonance imaging. Front. Radiol. 1, 735567 (2021).","journal-title":"Front. Radiol."},{"key":"51568_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112122","volume":"16","author":"I Washington","year":"2024","unstructured":"Washington, I. et al. The role of MRI in breast cancer and breast conservation therapy. Cancers (Basel) 16, 2122 (2024).","journal-title":"Cancers (Basel)"},{"key":"51568_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/jamainternmed.2019.5284","volume":"180","author":"SA Woolen","year":"2020","unstructured":"Woolen, S. A. et al. Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: A systematic review and meta-analysis. JAMA Intern. Med. 180, 223\u2013230 (2020).","journal-title":"JAMA Intern. Med."},{"key":"51568_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/MNH.0000000000000475","volume":"28","author":"K Leyba","year":"2019","unstructured":"Leyba, K. & Wagner, B. Gadolinium-based contrast agents: Why nephrologists need to be concerned. Curr. Opin. Nephrol. Hypertens. 28, 154\u2013162 (2019).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"51568_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/RLI.0000000000000465","volume":"53","author":"K Pinker","year":"2018","unstructured":"Pinker, K. et al. Diffusion-weighted imaging with apparent diffusion coefficient mapping for breast cancer detection as a stand-alone parameter: Comparison with dynamic contrast-enhanced and multiparametric magnetic resonance imaging. Invest. Radiol. 53, 587\u2013595 (2018).","journal-title":"Invest. Radiol."},{"key":"51568_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52785-3","volume":"9","author":"NP Pereira","year":"2019","unstructured":"Pereira, N. P. et al. Diffusion-weighted magnetic resonance imaging of patients with breast cancer following neoadjuvant chemotherapy provides early prediction of pathological response \u2013 A prospective study. Sci. Rep. 9, 16372 (2019).","journal-title":"Sci. Rep."},{"key":"51568_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6195-y","volume":"19","author":"A Surov","year":"2019","unstructured":"Surov, A., Meyer, H. J. & Wienke, A. Can apparent diffusion coefficient distinguish breast cancer from benign lesions? A meta-analysis of 13,847 lesions. BMC Cancer 19, 1018 (2019).","journal-title":"BMC Cancer"},{"key":"51568_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ejrnm.2015.10.013","volume":"47","author":"AM Osman","year":"2016","unstructured":"Osman, A. M. & Shebrya, N. H. Value of diffusion weighted imaging and apparent diffusion coefficient in differentiation between solid benign and malignant breast lesions. Egypt. J. Radiol. Nucl. Med. 47, 363\u2013371 (2016).","journal-title":"Egypt. J. Radiol. Nucl. Med."},{"key":"51568_CR13","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/mrm.22740","volume":"65","author":"EE Sigmund","year":"2011","unstructured":"Sigmund, E. E. et al. Intravoxel incoherent motion imaging of tumor microenvironment in locally advanced breast cancer. Magn. Reson. Med. 65, 1437\u20131447 (2011).","journal-title":"Magn. Reson. Med."},{"key":"51568_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/jmri.26908","volume":"52","author":"M Iima","year":"2020","unstructured":"Iima, M., Honda, M. & Sigmund, E. E. Diffusion MRI of the breast: Current status and future directions. J. Magn. Reson. Imaging. 52, 70\u201390 (2020).","journal-title":"J. Magn. Reson. Imaging"},{"key":"51568_CR15","doi-asserted-by":"publisher","first-page":"572090","DOI":"10.3389\/fonc.2020.585486","volume":"10","author":"J Liang","year":"2020","unstructured":"Liang, J. et al. IVIM diffusion-weighted imaging for quantitative differentiation of breast tumors: a meta-analysis. Front. Oncol. 10, 572090 (2020).","journal-title":"Front. Oncol."},{"key":"51568_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mri.2017.12.018","volume":"48","author":"Y Kim","year":"2018","unstructured":"Kim, Y. et al. Intravoxel incoherent motion diffusion-weighted MRI for predicting response to neoadjuvant chemotherapy in breast cancer. Magn. Reson. Imaging 48, 27\u201333 (2018).","journal-title":"Magn. Reson. Imaging"},{"key":"51568_CR17","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.3390\/cancers14143515","volume":"14","author":"L Guo","year":"2022","unstructured":"Guo, L. et al. Delta-radiomics based on dynamic contrast-enhanced MRI predicts pathologic complete response in breast cancer patients treated with neoadjuvant chemotherapy. Cancers 14, 3515 (2022).","journal-title":"Cancers"},{"key":"51568_CR18","volume":"13","author":"Y Chen","year":"2023","unstructured":"Chen, Y., Qi, Y. & Wang, K. Evaluation and progress of neoadjuvant chemotherapy for breast cancer. Front. Oncol. 13, 1279933 (2023).","journal-title":"Front. Oncol."},{"key":"51568_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2022.110372","volume":"154","author":"R Ota","year":"2022","unstructured":"Ota, R. et al. Evaluation of pathological complete response after neoadjuvant systemic treatment of invasive breast cancer using diffusion-weighted imaging compared with dynamic contrast-enhanced based kinetic analysis. Eur. J. Radiol. 154, 110372 (2022).","journal-title":"Eur. J. Radiol."},{"key":"51568_CR20","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1007\/s00330-023-09675-0","volume":"33","author":"H Bickel","year":"2023","unstructured":"Bickel, H. et al. Breast ADC category system (ADC-B) derived from a multicentre MRI database. Eur. Radiol. 33, 5400\u20135410 (2023).","journal-title":"Eur. Radiol."},{"key":"51568_CR21","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.2174\/1573405618666220415130131","volume":"18","author":"K Rahmat","year":"2022","unstructured":"Rahmat, K. et al. MRI breast: Current imaging trends, clinical applications, and future research directions. Curr. Med. Imaging 18, 1347\u20131361 (2022).","journal-title":"Curr. Med. Imaging"},{"key":"51568_CR22","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3390\/jcm9061853","volume":"9","author":"D Leithner","year":"2020","unstructured":"Leithner, D. et al. Non-invasive assessment of breast cancer molecular subtypes with multiparametric MRI radiomics: a feasibility study. J. Clin. Med. 9, 1853 (2020).","journal-title":"J. Clin. Med."},{"key":"51568_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1148\/radiol.2018180273","volume":"289","author":"SC Partridge","year":"2018","unstructured":"Partridge, S. C. et al. Diffusion-weighted MRI findings predict pathological response to neoadjuvant chemotherapy in breast cancer: The ACRIN 6698 trial. Radiology 289, 618\u2013627 (2018).","journal-title":"Radiology"},{"key":"51568_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1148\/radiol.243824","volume":"316","author":"T Ramtohul","year":"2025","unstructured":"Ramtohul, T. et al. Posttreatment MRI to predict pathologic complete response of triple-negative breast cancer to neoadjuvant chemoimmunotherapy. Radiology 316, 142\u2013152 (2025).","journal-title":"Radiology"},{"key":"51568_CR25","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/jmri.26539","volume":"49","author":"DC Newitt","year":"2019","unstructured":"Newitt, D. C. et al. Repeatability and reproducibility of ADC histogram metrics from the ACRIN 6698 breast cancer therapy response trial. J. Magn. Reson. Imaging. 49, 1617\u20131628 (2019).","journal-title":"J. Magn. Reson. Imaging"},{"key":"51568_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174271","volume":"13","author":"F Pesapane","year":"2021","unstructured":"Pesapane, F. et al. Radiomics of MRI for the prediction of the pathological response to neoadjuvant chemotherapy in breast cancer patients: A single referral centre analysis. Cancers (Basel) 13, 4271 (2021).","journal-title":"Cancers (Basel)"},{"key":"51568_CR27","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.242969","volume":"316","author":"X Gong","year":"2025","unstructured":"Gong, X. et al. Comparing multi\u2013b-value diffusion MRI models for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Radiology 316, e242969 (2025).","journal-title":"Radiology"},{"key":"51568_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.70296","volume":"26","author":"J Zhang","year":"2025","unstructured":"Zhang, J. et al. MRI-based radiomics models for early predicting pathological response to neoadjuvant chemotherapy in triple-negative breast cancer: A systematic review and meta-analysis. J. Appl. Clin. Med. Phys. 26, e70296 (2025).","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"51568_CR29","first-page":"47","volume":"16","author":"HJ Meyer","year":"2021","unstructured":"Meyer, H. J., Wienke, A. & Surov, A. Diffusion-weighted imaging of different breast cancer molecular subtypes: A systematic review and meta-analysis. Breast Care (Basel) 16, 47\u201354 (2021).","journal-title":"Breast Care (Basel)"},{"key":"51568_CR30","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-1078","volume":"10","author":"X Geng","year":"2022","unstructured":"Geng, X. et al. Using the apparent diffusion coefficient histogram analysis to predict response to neoadjuvant chemotherapy in patients with breast cancer: Comparison among three region of interest selection methods. Ann. Transl. Med. 10, 323 (2022).","journal-title":"Ann. Transl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51568-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:26:35Z","timestamp":1786487195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51568-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51568"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51568-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24944"}}